The Potency of Semax Peptide Therapy toward MDA Level and Protein Profile in Epilepsy Rats (Rattus norvegicus)
- DOI
- 10.2991/icoh-17.2018.59How to use a DOI?
- Keywords
- epilepsy, brain, LiCl, pilocarpine, semax peptide, malondyaldehyde, proteins profile
- Abstract
Epilepsy is a disruption of brain function that is characterized by abnormal depolarization of neurons. One signs of epilepsy is seizures, it is caused by brain injury. Epilepsy can cause morbidity and mortality, so many drugs used to treat epilepsy. But these drugs have negative health effects. This research was using semax peptide as alternative therapy, because it is a neuropeptide that directly acts on the central nervous system and free from hormonal activity, so it were not cause negative health effects. Moreover semax peptide is an antioxidant and it can synthesize some proteins in brain. The potency of semax peptide therapy on epilepsy rats can be analyzed by MDA level and profil proteins in brain. The epilepsy rats were prepared by in vivo using LiCl and pilocarpine. Then rats treated with 50 æg/kg body weight dose semax peptide. Analysis of MDA level were measured using TBA test while protein profile were determined using SDS-PAGE method. The result showed that semax peptide were reduce MDA level up to 40.46% and synthesize 3 kinds of proteins were not synthesized on epilepsy rats. Those proteins have molecular weights of 93.54 kDa, 66.76 kDa, and 59.66 kDa. In Conclusion, 50 æg/kg body weight dose semax peptide can be used for the treatment of epilepsy.
- Copyright
- © 2018, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Ratna Puspita AU - Dian Pratamastuti AU - Anna Safitri AU - Aulanni'am Aulanni'am PY - 2017/07 DA - 2017/07 TI - The Potency of Semax Peptide Therapy toward MDA Level and Protein Profile in Epilepsy Rats (Rattus norvegicus) BT - Proceedings of the 1st International Conference in One Health (ICOH 2017) PB - Atlantis Press SP - 294 EP - 298 SN - 2468-5739 UR - https://doi.org/10.2991/icoh-17.2018.59 DO - 10.2991/icoh-17.2018.59 ID - Puspita2017/07 ER -